Cargando…
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
Discovery of therapeutic antibodies is a field of intense development, where immunization of rodents remains a major source of antibody candidates. However, high orthologue protein sequence homology between human and rodent species disfavors generation of antibodies against functionally conserved bi...
Autores principales: | Gjetting, Torben, Gad, Monika, Fröhlich, Camilla, Lindsted, Trine, Melander, Maria C, Bhatia, Vikram K, Grandal, Michael M, Dietrich, Nikolaj, Uhlenbrock, Franziska, Galler, Gunther R, Strandh, Magnus, Lantto, Johan, Bouquin, Thomas, Horak, Ivan D, Kragh, Michael, Pedersen, Mikkel W, Koefoed, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6601539/ https://www.ncbi.nlm.nih.gov/pubmed/31046547 http://dx.doi.org/10.1080/19420862.2019.1596514 |
Ejemplares similares
-
CD4(+) and CD8a(+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models
por: Kristensen, Lotte K., et al.
Publicado: (2019) -
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018) -
In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography
por: Nielsen, Carsten H., et al.
Publicado: (2015) -
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
por: Reddy, Tejaswini P., et al.
Publicado: (2020) -
William George Sym
Publicado: (1938)